Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.
Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.
No grade 3 or higher treatment-related adverse effects or deaths were reported among those with non-muscle invasive bladder cancer in the BOND-003 trial.